NYSEMKT: SERSerina Therapeutics Inc Stock
$5.75+0.00 (+0%)
Updated May 8, 2025
SER Price
$5.75
Fair Value Price
N/A
Market Cap
$57.26M
52 Week Low
$3.81
52 Week High
$14.57
P/E
574.5x
P/B
33.66x
P/S
1,084.64x
PEG
N/A
Dividend Yield
N/A
Revenue
$51.00k
Earnings
-$939.00k
Gross Margin
100%
Operating Margin
-1,301.96%
Profit Margin
-1,841.2%
Debt to Equity
3.04
Operating Cash Flow
-$20M
Beta
0.35
Next Earnings
May 12, 2025
Ex-Dividend
N/A
Next Dividend
N/A
SER Overview
AgeX Therapeutics, Inc. operates as a biotechnology company. The company is headquartered in Alameda, California and currently employs 12 full-time employees. The firm is focused on the development and commercialization of therapeutics targeting human aging. Its induced Tissue Regeneration (iTR) technology is based telomerase-mediated cellular immortality and regenerative biology. Its pipeline includes two cell-based, two drug-based therapeutic products, online database products and research products. The Company’s AGEX-BAT1 is its cell therapy product candidate that is being developed for the treatment of certain age-related metabolic disorders, such as Type II (adult-onset) diabetes. AGEX-VASC1 is its cell-based therapy that is designed to restore vascular support in aged ischemic tissues such as the aging heart. AGEX-iTR1547 is its drug-based formulation developed to restore regenerative potential in an array of aged tissues afflicted with degenerative disease using its proprietary iTR technology. Renelon is its iTR product candidate designed to promote scar less tissue repair.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SER's potential to beat the market
- SER doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
SER
RankedUnranked of 457
RankedUnranked of 457
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.89 | A | |
| $42.51 | A | |
| $8.11 | A |
Be the first to know about important SER news, forecast changes, insider trades & much more!
SER News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SER scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SER was unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
SER is poor value based on its earnings relative to its share price (574.5x), compared to the US market average (24.22x)
P/E vs Market Valuation
SER is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more SER due diligence checks available for Premium users.
Valuation
SER price to earnings (PE)
For valuing profitable companies with steady earnings
Company
574.5x
Industry
-168.76x
Market
24.22x
SER is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
SER is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
SER price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
33.66x
Industry
4.15x
SER is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SER's financial health
Profit margin
Revenue
$0.0
Net Income
-$4.8M
Profit Margin
0%
SER's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
SER's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$6.7M
Liabilities
$5.2M
Debt to equity
3.04
SER's short-term assets ($5.75M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SER's short-term assets ($5.75M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SER's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
SER's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.3M
Investing
$0.0
Financing
$4.9M
SER's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SER vs Biotech Stocks
Serina Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.